Acetic acid, propylene glycol diacetate, and hydrocortisone

Acetic acid, propylene glycol diacetate, and hydrocortisone: Drug information
Copyright 1978-2011 Lexicomp, Inc. All rights reserved.
(For additional information see “Acetic acid, propylene glycol diacetate, and hydrocortisone: Patient drug information”)

Brand Names: U.S. Acetasol® HC; VoSol® HC
Pharmacologic Category Otic Agent, Anti-infective
Dosing: Adult Otitis externa (superficial): Otic: Instill 3-5 drops in ear(s) every 4-6 hours
Dosing: Pediatric Children ≥3 years: Refer to adult dosing.
Dosing: Geriatric Refer to adult dosing.
Dosage Forms: U.S. Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, otic [drops]: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)

Acetasol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) [contains benzethonium chloride]

VoSol® HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) [contains benzethonium chloride]

Generic Equivalent Available: U.S. Yes
Administration After removing cerumen and debris, solution may be applied by inserting a cotton wick into the ear canal and saturating with the solution. Wick may remain in place for 24 hours and then removed; however, drops should continue to be instilled into ear canal as long as indicated.
Use Treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by swelling
Adverse Reactions Significant Frequency not defined: Otic: Transient burning or stinging may be noticed occasionally when the solution is first instilled into the acutely inflamed ear
Contraindications Hypersensitivity to acetic acid, propylene glycol, hydrocortisone, or any component of the formulation; perforated tympanic membrane; herpes simplex; vaccinia, and varicella
Metabolism/Transport Effects Hydrocortisone: Substrate of CYP3A4 (minor), P-glycoprotein; Induces CYP3A4 (weak)
Drug Interactions
(For additional information: Launch Lexi-Interact™ Drug Interactions Program )
Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Risk X: Avoid combination

BCG: Antibiotics may diminish the therapeutic effect of BCG. Risk X: Avoid combination

Conivaptan: May increase the serum concentration of CYP3A4 Substrates (Low risk). Risk C: Monitor therapy

Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Risk C: Monitor therapy

Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Risk C: Monitor therapy

Telaprevir: May increase the serum concentration of Corticosteroids. Corticosteroids may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended. When possible, consider alternatives. If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects. Risk D: Consider therapy modification

Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates. Risk C: Monitor therapy

Pricing: U.S. (www.drugstore.com)
Solution (Acetasol HC)

2-1% (10): $220.00